Prostamax common uses, half-life, side effects and more

Prostamax is a synthetic four amino acid peptide, the sequence Lys-Glu-Asp-Pro, also called KEDP. It is one of a family of very short peptides promoted by a single Russian research group, this one for prostate and urinary symptoms. It is not the same thing as the bovine prostate extract drugs sold under names like Prostatilen and Vitaprost. It is not the saw palmetto supplements sold under similar names either. Western sellers ship it as a powder to inject. No regulator has approved it anywhere. The FDA named one seller's Prostamax an unapproved new drug in 2026. Nobody has run a controlled human trial of it.

• Benign prostate enlargement symptoms
• Prostatitis-type pelvic pain and inflammation
• Urinary stream, urgency, and nighttime urination
• Sexual function and libido as a marketing claim

Once daily in short courses of two to six weeks

No validated human dose exists. The only documented human dosing sits inside an inventor patent at 0.01 to 100 micrograms per kilogram into muscle once daily for 10 to 40 days in two small uncontrolled patient groups. Rat prostate studies injected about 20 micrograms per kilogram into muscle. Scaling that lands near 200 micrograms a day for an adult. Sellers list 1 to 2 milligrams a day injected under the skin. That runs several times higher than the scaled animal dose and traces to a course length borrowed from the prostate extract drugs rather than to any study of this peptide.

No measured half-life exists for Prostamax in any species. No pharmacokinetic study of it exists. Short peptides in this family are expected to break down quickly in the body. Nobody has measured whether this one does.

• No side effect has been recorded in a person because no controlled human study exists
• The inventor's own animal testing reported no harm at doses many times the proposed one
• That testing never examined the prostate itself and never checked for DNA damage
• One study in human cells found a marker of DNA damage roughly doubled after exposure
• The rat prostate studies measured only benefit and never looked for harm

KEDP has no validated receptor and no established prostate mechanism. Its strongest molecular finding is a change in blood lymphocytes rather than in prostate cells. Peptide added to lymphocytes from elderly donors shifted a heating curve that the authors read as chromatin loosening. The same laboratory found five different peptides all produce that shift. It is not specific to this sequence. A toxic metal produces the same shift through cell damage and another metal moves it the opposite way. The readout is generic rather than a signature of a designed effect. Rat studies report smaller and less inflamed prostates as outcomes and measured no receptor, pathway, or gene. Whether the intact peptide survives the blood and reaches the prostate has never been tested.

The evidence is weak and comes mostly from one Russian research tradition. Most of what circulates as prostate peptide research is actually about a different product, a bovine prostate extract, rather than this synthetic peptide. The chromatin work is a single collaboration that began with the developer as a co-author. The two rat prostate studies are the only prostate-outcome evidence. One is independent by authorship. The other carries a co-author from a St. Petersburg drug company. Neither says where its peptide came from. Both ran in a journal with a documented reputation for publishing without real peer review. Nobody has repeated either result in over a decade. No controlled human trial exists. The only human data is 51 patients across two inventor patents. None of it was blinded or placebo-controlled.

• No controlled human study has been run and nothing is known about what it does in people
• Elevated PSA, blood in urine, urinary retention, fever, or worsening urinary symptoms need a doctor rather than a peptide
• Cancer risk is untested even though it targets the prostate in the age group most likely to carry hidden prostate cancer and it doubled a DNA-damage marker in human cells
• The FDA named a marketed Prostamax an unapproved new drug in 2026
• Anti-doping rules do not name it but the catch-all for unapproved substances reaches it because it holds no medicine approval anywhere
• Research vials may carry the wrong sequence, the wrong dose, or contamination